Published on
June 2, 2017
- 20:27 GMT
Innate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S
INNATE PHARMA STRENGTHENS ITS PROPRIETARY PIPELINE WITH THE ACQUISITION OF ANTI-C5aR, A FIRST-IN-CLASS CLINICAL-STAGE ANTIBODY, FROM NOVO NORDISK A/S Anti-C5a receptor (C5aR) is a first-in-class clinical-stage monoclonal antibody (mAb) targeting myeloid- …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Technology
